An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
Completed · Phase 3 · NCT02632409
Conditions: Various Advanced Cancer
At a glance
- Research payments reported, 2025
- $12,545
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 709
About the trial
- Sponsor
- Bristol-Myers Squibb (with Ono Pharmaceutical Co., Ltd.)
- Tested
- Nivolumab (biological), Placebo (other)
- Dates
- Started 2016-03-22; completion 2026-05-19
- Results posted
- Yes
The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer.
From ClinicalTrials.gov, last updated 2026-07-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $12,545 in research payments for this study in 2025 (8 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nauman Moazzam, MD Hematology & Oncology · Lakewood, CO
- Rahul Ravilla, M.D Hematology & Oncology · Albany, NY
- Ian D. Schnadig, M.D. Hematology & Oncology · Tualatin, OR
- Mark T. Fleming, MD Hematology & Oncology · Hampton, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rocky Mountain Cancer Centers LLP $3,890
- New York Oncology Hematology, PC $3,555
- Northwest Cancer Specialists, PC $2,550
- Virginia Oncology Associates $2,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.